risk‐based approach to managing active pharmaceutical ingredients in manufacturing effluent
The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools...
Saved in:
Published in | Environmental toxicology and chemistry Vol. 35; no. 4; pp. 813 - 822 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Pergamon
01.04.2016
Blackwell Publishing Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of “no discharge of APIs in toxic amounts.” The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic. Environ Toxicol Chem 2016;35:813–822. © 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC. |
---|---|
AbstractList | The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of "no discharge of APIs in toxic amounts." The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic. The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of “no discharge of APIs in toxic amounts.” The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic. Environ Toxicol Chem 2016;35:813–822. © 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC. The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of "no discharge of APIs in toxic amounts." The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic.The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of "no discharge of APIs in toxic amounts." The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic. The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts of active pharmaceutical ingredients (APIs) in wastewater from manufacturing operations, including those from external suppliers. The tools are not a substitute for compliance with local regulatory requirements but rather are intended to help manufacturers achieve the general standard of "no discharge of APIs in toxic amounts." The approaches detailed in the present study identify practices for assessing potential environmental risks from APIs in manufacturing effluent and outline measures that can be used to reduce the risk, including selective application of available treatment technologies. These measures either are commonly employed within the industry or have been implemented to a more limited extent based on local circumstances. Much of the material is based on company experience and case studies discussed at an industry workshop held on this topic. Environ Toxicol Chem 2016; 35:813-822. copyright 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC. |
Author | Murray-Smith, Richard Straub, Jürg Oliver Mattson, Bengt Wiedemann, Michael Mastrocco, Frank Kappler, Kelly Dolan, David G. Wilson, Peter Meyerhoff, Roger D. Hartmann, Andreas Journel, Romain Finan, Douglas S. Senac, Thomas Parke, Neil J. Caldwell, Daniel J. Mertens, Birgit |
Author_xml | – sequence: 1 givenname: Daniel J. surname: Caldwell fullname: Caldwell, Daniel J. email: dcaldwel@its.jnj.com organization: Johnson & Johnson, NJ, New Brunswick, USA – sequence: 2 givenname: Birgit surname: Mertens fullname: Mertens, Birgit organization: Janssen Pharmaceutical Companies of Johnson & Johnson, Belgium, Beerse – sequence: 3 givenname: Kelly surname: Kappler fullname: Kappler, Kelly organization: Johnson & Johnson Consumer Group of Companies, New Jersey, Skillman, USA – sequence: 4 givenname: Thomas surname: Senac fullname: Senac, Thomas organization: Sanofi, France, Paris – sequence: 5 givenname: Romain surname: Journel fullname: Journel, Romain organization: Sanofi, France, Paris – sequence: 6 givenname: Peter surname: Wilson fullname: Wilson, Peter organization: Sanofi Bridgewater, New Jersey, USA – sequence: 7 givenname: Roger D. surname: Meyerhoff fullname: Meyerhoff, Roger D. organization: Eli Lilly, Indiana, Indianapolis, USA – sequence: 8 givenname: Neil J. surname: Parke fullname: Parke, Neil J. organization: Eli Lilly, Indiana, Indianapolis, USA – sequence: 9 givenname: Frank surname: Mastrocco fullname: Mastrocco, Frank organization: Pfizer, New York, New York, USA – sequence: 10 givenname: Bengt surname: Mattson fullname: Mattson, Bengt organization: LIF, Swedish Association of the Pharmaceutical Industry, Sweden, Stockholm – sequence: 11 givenname: Richard surname: Murray-Smith fullname: Murray-Smith, Richard organization: AstraZeneca, United Kingdom, Alderley Park – sequence: 12 givenname: David G. surname: Dolan fullname: Dolan, David G. organization: Amgen, California, Thousand Oaks, USA – sequence: 13 givenname: Jürg Oliver surname: Straub fullname: Straub, Jürg Oliver organization: F. Hoffmann-La Roche, Basel, Switzerland – sequence: 14 givenname: Michael surname: Wiedemann fullname: Wiedemann, Michael organization: Bayer HealthCare, Leverkusen, Germany – sequence: 15 givenname: Andreas surname: Hartmann fullname: Hartmann, Andreas organization: Novartis, Basel, Switzerland – sequence: 16 givenname: Douglas S. surname: Finan fullname: Finan, Douglas S. organization: GSK, Research Triangle Park, North Carolina, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26183919$$D View this record in MEDLINE/PubMed |
BookMark | eNqN0ttqFTEUBuAgFbtbBZ9AB7zpzWxzmMnhUopWoeqFVkGQsCaH3bSzZ7ZJpto7H8Fn9EnMsGvFouhVAutbOfCvPbQzjIND6D7BS4IxfeyyWTLC2S20IG1La8mJ3EELLBiuBeVyF-2ldIYx4UqpO2iXljpTRC3QxxjS-fev3zpIzlaw2cQRzGmVx2oNA6zCsKrA5HDhqs0pxDUYN-VgoK9KJTob3JBT2c968kVOcW5x3vdTKd1Ftz30yd27WvfRybOnbw-f18evj14cPjmuDScNq62hqjPK2w4LaznuFONcdlK4RvEGAOPWG8YYN5ZY2hGrvFe2BWO9lMITto8OtueW53-aXMp6HZJxfQ-DG6ekicSSCUx5-z-UkVayRv2bCtFyRjCVhT66Qc_GKQ7lz7NqJOaKNUU9uFJTt3ZWb2JYQ7zUP-P4daOJY0rR-WtCsJ6T1iVpPSdd6PIGNSFDDuOQI4T-Tw31tuFz6N3lXw_WxfzuQ8ruy7WHeK65YKLV718dafZS4XeEtfpD8Q-33sOoYVXmSp-8oWXkytg1gtOW_QD0zdGR |
CitedBy_id | crossref_primary_10_1590_0103_11042019s312 crossref_primary_10_1016_j_yrtph_2018_09_014 crossref_primary_10_1155_2024_5538398 crossref_primary_10_2174_2667337108666211206151551 crossref_primary_10_1061__ASCE_HZ_2153_5515_0000694 crossref_primary_10_1002_etc_3394 crossref_primary_10_1021_acs_chemrev_1c00631 crossref_primary_10_3390_w16233428 crossref_primary_10_1016_j_watres_2017_09_019 crossref_primary_10_1016_j_envres_2023_117747 crossref_primary_10_1002_ieam_4560 crossref_primary_10_1016_j_scitotenv_2021_151128 crossref_primary_10_1002_ieam_4141 crossref_primary_10_1007_s10311_021_01194_y crossref_primary_10_1515_limre_2017_0010 crossref_primary_10_1007_s13201_022_01594_7 crossref_primary_10_1016_j_scitotenv_2018_05_325 crossref_primary_10_1007_s13762_023_04880_2 crossref_primary_10_1016_j_jwpe_2019_101039 crossref_primary_10_7759_cureus_68215 crossref_primary_10_1248_yakushi_17_00177_4 crossref_primary_10_1007_s11356_016_6947_z crossref_primary_10_1016_j_scitotenv_2018_07_240 crossref_primary_10_1039_C7EW00077D crossref_primary_10_1007_s13762_017_1393_0 crossref_primary_10_1007_s11270_024_07606_3 crossref_primary_10_1016_j_scitotenv_2019_134815 crossref_primary_10_1016_j_talanta_2019_120382 crossref_primary_10_1016_j_trac_2018_02_013 |
Cites_doi | 10.1016/j.ecoenv.2010.05.012 10.1016/j.scitotenv.2012.07.086 10.2166/wst.2011.054 10.1002/ieam.1551 10.1016/j.yrtph.2005.05.005 10.1002/ieam.1268 10.1016/j.chemosphere.2014.02.004 10.1016/j.aquatox.2005.09.009 10.1007/BF03326250 10.1021/es203987b 10.1002/ieam.1311 10.1289/ehp.1104477 10.1016/j.envint.2009.09.002 10.1016/j.jhazmat.2007.07.008 10.1021/es100356f 10.1016/j.envpol.2013.09.013 10.1016/j.envint.2011.06.002 10.1098/rstb.2013.0571 |
ContentType | Journal Article |
Copyright | 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of SETAC. 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC. 2016 SETAC |
Copyright_xml | – notice: 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of SETAC. – notice: 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC. – notice: 2016 SETAC |
DBID | FBQ BSCLL 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7SN 7SS 7ST 7T7 7TK 7U7 8FD C1K FR3 K9. P64 RC3 SOI 7X8 7S9 L.6 |
DOI | 10.1002/etc.3163 |
DatabaseName | AGRIS Istex Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Ecology Abstracts Entomology Abstracts (Full archive) Environment Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts Environment Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Ecology Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management Entomology Abstracts Genetics Abstracts Biotechnology Research Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Environment Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic AGRICOLA Technology Research Database Entomology Abstracts |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Ecology |
EISSN | 1552-8618 |
EndPage | 822 |
ExternalDocumentID | 3992787611 26183919 10_1002_etc_3163 ETC3163 ark_67375_WNG_3M90V135_Z US201600147625 |
Genre | reviewArticle Journal Article Review |
GrantInformation_xml | – fundername: Whitehouse Station, NJ, USA |
GroupedDBID | --- --K -~X ..I .3N .GA .Y3 05W 0R~ 10A 1B1 1OB 1OC 29G 31~ 33P 36B 3SF 3V. 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5VS 66C 702 7PT 7X2 7X7 7XC 8-0 8-1 8-3 8-4 8-5 88E 88I 8C1 8FE 8FG 8FH 8FI 8FJ 8G5 8R4 8R5 8UM 8WZ 930 A03 A6W AAESR AAEVG AAFWJ AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCUV ABEFU ABHUG ABJCF ABJNI ABPTK ABPVW ABUWG ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOD ACIWK ACPOU ACPRK ACXBN ACXME ACXQS ADAWD ADBBV ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFKRA AFPWT AFRAH AFVGU AFZJQ AGJLS AHMBA AI. AIAGR AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATCPS ATUGU AUFTA AVWKF AZBYB AZFZN AZQEC AZVAB BAFTC BDRZF BENPR BFHJK BGLVJ BHBCM BHPHI BMNLL BMXJE BNHUX BPHCQ BROTX BRXPI BVXVI BY8 CAG CCPQU COF CS3 D-E D-F D0L D1I DCZOG DPXWK DR2 DRFUL DRSTM DU5 DWQXO EBS ECGQY EJD F00 F01 F04 F5P FBQ FEDTE FYUFA G-S G.N GNUQQ GODZA GUQSH GWYGA H.T H.X HCIFZ HF~ HMCUK HVGLF HZ~ IHE IX1 J0M KB. L6V LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M0K M1P M2O M2P M41 M7S MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB NQ- O66 O9- OHT P2P P2W P2X P4D PALCI PATMY PDBOC PQQKQ PROAC PSQYO PTHSS PYCSY Q.N Q11 Q2X QB0 R.K RIWAO RJQFR RNS ROL RPZ RWI RX1 SAMSI SUPJJ TWZ UB1 UKHRP VH1 W8V W99 WBKPD WH7 WIH WIK WOHZO WRC WUPDE WXSBR WYISQ XG1 XIH XV2 YCJ ZZTAW ~02 ~IA ~KM ~WT AAHBH ABEJV AHBTC AITYG ALIPV BSCLL HGLYW 24P 5WD AANHP AAYCA ABDFA ABXVV ACRPL ACYXJ ADIPN ADNMO AEUYN AFWVQ ALVPJ OBOKY OWPYF ROX AAYXX ABGNP AGORE AGQPQ BCRHZ CITATION KOP AAMMB ACVCV AEFGJ AGHNM AGXDD AIDQK AIDYY AJBYB AJDVS CGR CUY CVF ECM EIF H13 NPM PHGZM PHGZT PJZUB PPXIY PQGLB 7QO 7SN 7SS 7ST 7T7 7TK 7U7 8FD C1K FR3 K9. P64 RC3 SOI 7X8 7S9 L.6 |
ID | FETCH-LOGICAL-c6143-dc29bc9fdb07dd60b93668b87e4964aa005fc3336cd1d2b1d9ff9d5acdf887f13 |
IEDL.DBID | DR2 |
ISSN | 0730-7268 1552-8618 |
IngestDate | Fri Jul 11 13:40:32 EDT 2025 Fri Jul 11 18:26:17 EDT 2025 Fri Jul 11 01:34:34 EDT 2025 Wed Aug 13 11:10:28 EDT 2025 Mon Jul 21 06:06:35 EDT 2025 Thu Apr 24 22:53:13 EDT 2025 Tue Jul 01 01:49:49 EDT 2025 Wed Jan 22 16:35:31 EST 2025 Wed Oct 30 09:51:21 EDT 2024 Wed Dec 27 19:26:43 EST 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Wastewater effluent Active pharmaceutical ingredient Maturity path |
Language | English |
License | Attribution-NonCommercial-NoDerivs https://creativecommons.org/licenses/by-nc-nd/4.0 2015 The Authors. Environmental Toxicology and Chemistry Published by Wiley Periodicals, Inc. on behalf of SETAC. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c6143-dc29bc9fdb07dd60b93668b87e4964aa005fc3336cd1d2b1d9ff9d5acdf887f13 |
Notes | http://dx.doi.org/10.1002/etc.3163 ark:/67375/WNG-3M90V135-Z istex:3C175B89615A1E8A50D2315B3777C08065BF658B Whitehouse Station, NJ, USA ArticleID:ETC3163 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fetc.3163 |
PMID | 26183919 |
PQID | 1774806934 |
PQPubID | 32741 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1808370265 proquest_miscellaneous_1803158349 proquest_miscellaneous_1775631028 proquest_journals_1774806934 pubmed_primary_26183919 crossref_primary_10_1002_etc_3163 crossref_citationtrail_10_1002_etc_3163 wiley_primary_10_1002_etc_3163_ETC3163 istex_primary_ark_67375_WNG_3M90V135_Z fao_agris_US201600147625 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | April 2016 |
PublicationDateYYYYMMDD | 2016-04-01 |
PublicationDate_xml | – month: 04 year: 2016 text: April 2016 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Oxford |
PublicationTitle | Environmental toxicology and chemistry |
PublicationTitleAlternate | Environ Toxicol Chem |
PublicationYear | 2016 |
Publisher | Pergamon Blackwell Publishing Ltd |
Publisher_xml | – name: Pergamon – name: Blackwell Publishing Ltd |
References | Cardoso O, Porcher JM, Sanchez W. 2014. Factory-discharged pharmaceuticals could be a relevant source of aquatic environment contamination: Review of evidence and need for knowledge. Chemosphere 115:20-30. Deegan AM, Shaik B, Nolan K, Urell K, Oelgemöller M, Tobin J, Morrissey A. 2011. Treatment options for wastewater effluents from pharmaceutical companies. Int J Environ Sci Tech 8:649-666. Phillips PJ, Smith SG, Kolpin DW, Zaugg SD, Buxton HT, Furlong ET, Esposito K, Stinson B. 2010. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ Sci Technol 44:4910-4916. Kostich MS, Batt AL, Lazorchak JM. 2014. Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation. Environ Pollut 184C:354-359. Martz M. 2012. Effective wastewater treatment in the pharmaceutical industry. Pharm Eng 32:1-12. US Environmental Protection Agency. 1995. Final Water Quality Guidance for the Great Lakes System. Final Rule. 40 CFR Part 9. Fed Reg 60:15365-15425. Monteiro SC, Boxall ABA. 2010. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 202:53-154. Tischler L, Buzby M, Finan DS, Cunningham VL. 2013. Landfill disposal of unused medicines reduces surface water releases. Integr Environ Assess Manag 9:142-154. US Environmental Protection Agency. 2008. Drinking Water Contaminant Candidate List 3-Draft. Fed Reg 73:9628-9654. Gros M, Petrovic M, Ginebreda A, Barcelo D. 2010. Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environ Int 36:15-26. Lundstrom E, Adolfsson-Erici M, Alsberg T, Bjorlenius B, Eklund B, Laven M, Breitholtz M. 2010. Characterization of additional sewage treatment technologies: Ecotoxicological effects and levels of selected pharmaceuticals, hormones and endocrine disruptors. Ecotoxicol Environ Saf 73:1612-1619. Oppenheimer J, Stephenson R. 2006. Time out: Longer solids retention times can remove some PPCPs. Water Environment and Technology 18:77-82. Larsson DG, de Pedro C, Paxeus N. 2007. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 148:751-755. Sanchez W, Sremski W, Piccini B, Palluel O, Maillot-Marechal E, Betoulle S, Jaffal A, Ait-Aissa S, Brion F, Thybaud E, Hinfray N, Porcher JM. 2011. Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. Environ Int 37:1342-1348. US Environmental Protection Agency. 2009. Drinking Water Contaminant Candidate List 3-Final. Fed Reg 74:51850-51862. Sarp S, Chon K, Kim IS, Cho J. 2011. Advanced treatment of membrane bioreactor (MBR) effluents for effective wastewater reclamation. Water Sci Technol 63:303-310. Rudd MA, Ankley GT, Boxall AB, Brooks BW. 2014. International scientists' priorities for research on pharmaceutical and personal care products in the environment. Integr Environ Assess Manag 10:576-587. Larsson DG. 2014. Pollution from drug manufacturing: Review and perspectives. Philos Trans R Soc Lond B Biol Sci 369:20130571. Fent K, Weston AA, Caminada D. 2006. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 76:122-159. Gardner M, Comber S, Scrimshaw MD, Cartmell E, Lester J, Ellor B. 2012. The significance of hazardous chemicals in wastewater treatment works effluents. Sci Total Environ 437:363-372. Cook SM, VanDuinen BJ, Love NG, Skerlos SJ. 2012. Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals. Environ Sci Technol 46:5535-5541. US Environmental Protection Agency. 2012. Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for public water systems. Final Rule. 40 CFR Parts 141 and 142. Fed Reg 77:26072-26101. Murray-Smith RJ, Coombe VT, Gronlund MH, Waern F, Baird JA. 2012. Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach. Integr Environ Assess Manag 8:320-330. Schwab BW, Hayes EP, Fiori JM, Mastrocco FJ, Roden NM, Cragin D, Meyerhoff RD, D'Aco VJ, Anderson PD. 2005. Human pharmaceuticals in US surface waters: A human health risk assessment. Regul Toxicol Pharmacol 42:296-312. Boxall AB, Rudd MA, Brooks BW, Caldwell DJ, Choi K, Hickmann S, Innes E, Ostapyk K, Staveley JP, Verslycke T, Ankley GT, Beazley KF, Belanger SE, Berninger JP, Carriquiriborde P, Coors A, Deleo PC, Dyer SD, Ericson JF, Gagne F, Giesy JP, Gouin T, Hallstrom L, Karlsson MV, Larsson DG, Lazorchak JM, Mastrocco F, McLaughlin A, McMaster ME, Meyerhoff RD, Moore R, Parrott JL, Snape JR, Murray-Smith R, Servos MR, Sibley PK, Straub JO, Szabo ND, Topp E, Tetreault GR, Trudeau VL, Van Der Kraak G. 2012. Pharmaceuticals and personal care products in the environment: What are the big questions? Environ Health Perspect 120:1221-1229. US Environmental Protection Agency. 2015. Drinking Water Contaminant Candidate List 4-Draft. Fed Reg 80:6076-6084. European Commission. 2010. Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emissions (integrated pollution prevention and control). Official J Eur Union L334:17-119. 2007; 148 2012; 120 2010; 36 2012 2011 2006; 76 2010 2010; 202 2014; 184C 1998 2009 2008 2005; 42 2007 2006; 18 2006 1995 2011; 37 2015; 80 1992 2008; 73 2012; 77 2011; 8 2012; 32 2014; 115 2013; 9 2010; 44 2014; 369 2009; 74 1995; 60 2010; L334 2011; 63 2016 2015 2014 2013 2012; 46 2012; 437 2010; 73 2012; 8 2014; 10 World Health Organization. (2025010315265570700_etc3163-bib-0021) 2011 European Commission. (2025010315265570700_etc3163-bib-0023) 2010; L334 European Commission. (2025010315265570700_etc3163-bib-0026) 2011 OSPAR Commision. (2025010315265570700_etc3163-bib-0040) 2007 Cardoso (2025010315265570700_etc3163-bib-0005) 2014; 115 European Commission. (2025010315265570700_etc3163-bib-0012) 2008 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0018) 2012; 77 Pharmaceutical Supply Chain Initiative. (2025010315265570700_etc3163-bib-0055) 2015 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0041) 2010 Ecologic Institute. (2025010315265570700_etc3163-bib-0013) 2013 Deegan (2025010315265570700_etc3163-bib-0043) 2011; 8 Organisation for Economic Co-operation and Development. (2025010315265570700_etc3163-bib-0048) 1992 Monteiro (2025010315265570700_etc3163-bib-0001) 2010; 202 Organisation for Economic Co-operation and Development. (2025010315265570700_etc3163-bib-0032) 2014 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0031) 1995 Larsson (2025010315265570700_etc3163-bib-0008) 2014; 369 Cook (2025010315265570700_etc3163-bib-0004) 2012; 46 Martz (2025010315265570700_etc3163-bib-0044) 2012; 32 Derksen (2025010315265570700_etc3163-bib-0045) 2013 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0024) 2014 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0025) 1995; 60 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0042) 2010 European Medicines Evaluation Agency. (2025010315265570700_etc3163-bib-0028) 2006 Phillips (2025010315265570700_etc3163-bib-0007) 2010; 44 US Food and Drug Administration. (2025010315265570700_etc3163-bib-0034) 2006 Lundstrom (2025010315265570700_etc3163-bib-0051) 2010; 73 Schwab (2025010315265570700_etc3163-bib-0030) 2005; 42 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0019) 2015; 80 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0033) 2014 Rudd (2025010315265570700_etc3163-bib-0057) 2014; 10 Malinowski (2025010315265570700_etc3163-bib-0052) 2009 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0017) 2009; 74 Larsson (2025010315265570700_etc3163-bib-0009) 2007; 148 European Commision. (2025010315265570700_etc3163-bib-0038) 2006 European Commission. (2025010315265570700_etc3163-bib-0047) 2006 Water Environment Research Foundation. (2025010315265570700_etc3163-bib-0011) 2015 Kostich (2025010315265570700_etc3163-bib-0050) 2014; 184C Boxall (2025010315265570700_etc3163-bib-0056) 2012; 120 Fent (2025010315265570700_etc3163-bib-0010) 2006; 76 European Commission. (2025010315265570700_etc3163-bib-0014) 2012 Sanchez (2025010315265570700_etc3163-bib-0006) 2011; 37 Innovative Medicines Initiative. (2025010315265570700_etc3163-bib-0015) 2015 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0046) 1998 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0037) 2014 US Food and Drug Administration. (2025010315265570700_etc3163-bib-0035) 2014 Oppenheimer (2025010315265570700_etc3163-bib-0053) 2006; 18 Gardner (2025010315265570700_etc3163-bib-0022) 2012; 437 Sarp (2025010315265570700_etc3163-bib-0054) 2011; 63 European Commision. (2025010315265570700_etc3163-bib-0039) 2014 European Medicines Agency. (2025010315265570700_etc3163-bib-0036) 2015 Caldwell (2025010315265570700_etc3163-bib-0003) 2016 Gros (2025010315265570700_etc3163-bib-0049) 2010; 36 European Chemicals Agency. (2025010315265570700_etc3163-bib-0027) 2011 US Environmental Protection Agency. (2025010315265570700_etc3163-bib-0016) 2008; 73 Tischler (2025010315265570700_etc3163-bib-0002) 2013; 9 European Commission. (2025010315265570700_etc3163-bib-0020) 2012 Murray-Smith (2025010315265570700_etc3163-bib-0029) 2012; 8 |
References_xml | – reference: Deegan AM, Shaik B, Nolan K, Urell K, Oelgemöller M, Tobin J, Morrissey A. 2011. Treatment options for wastewater effluents from pharmaceutical companies. Int J Environ Sci Tech 8:649-666. – reference: Fent K, Weston AA, Caminada D. 2006. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 76:122-159. – reference: US Environmental Protection Agency. 2008. Drinking Water Contaminant Candidate List 3-Draft. Fed Reg 73:9628-9654. – reference: Sanchez W, Sremski W, Piccini B, Palluel O, Maillot-Marechal E, Betoulle S, Jaffal A, Ait-Aissa S, Brion F, Thybaud E, Hinfray N, Porcher JM. 2011. Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges. Environ Int 37:1342-1348. – reference: Gros M, Petrovic M, Ginebreda A, Barcelo D. 2010. Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environ Int 36:15-26. – reference: Lundstrom E, Adolfsson-Erici M, Alsberg T, Bjorlenius B, Eklund B, Laven M, Breitholtz M. 2010. Characterization of additional sewage treatment technologies: Ecotoxicological effects and levels of selected pharmaceuticals, hormones and endocrine disruptors. Ecotoxicol Environ Saf 73:1612-1619. – reference: Murray-Smith RJ, Coombe VT, Gronlund MH, Waern F, Baird JA. 2012. Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach. Integr Environ Assess Manag 8:320-330. – reference: Rudd MA, Ankley GT, Boxall AB, Brooks BW. 2014. International scientists' priorities for research on pharmaceutical and personal care products in the environment. Integr Environ Assess Manag 10:576-587. – reference: US Environmental Protection Agency. 2012. Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for public water systems. Final Rule. 40 CFR Parts 141 and 142. Fed Reg 77:26072-26101. – reference: Oppenheimer J, Stephenson R. 2006. Time out: Longer solids retention times can remove some PPCPs. Water Environment and Technology 18:77-82. – reference: Larsson DG, de Pedro C, Paxeus N. 2007. Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 148:751-755. – reference: Larsson DG. 2014. Pollution from drug manufacturing: Review and perspectives. Philos Trans R Soc Lond B Biol Sci 369:20130571. – reference: US Environmental Protection Agency. 2015. Drinking Water Contaminant Candidate List 4-Draft. Fed Reg 80:6076-6084. – reference: Monteiro SC, Boxall ABA. 2010. Occurrence and fate of human pharmaceuticals in the environment. Rev Environ Contam Toxicol 202:53-154. – reference: Phillips PJ, Smith SG, Kolpin DW, Zaugg SD, Buxton HT, Furlong ET, Esposito K, Stinson B. 2010. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ Sci Technol 44:4910-4916. – reference: European Commission. 2010. Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emissions (integrated pollution prevention and control). Official J Eur Union L334:17-119. – reference: Tischler L, Buzby M, Finan DS, Cunningham VL. 2013. Landfill disposal of unused medicines reduces surface water releases. Integr Environ Assess Manag 9:142-154. – reference: Cardoso O, Porcher JM, Sanchez W. 2014. Factory-discharged pharmaceuticals could be a relevant source of aquatic environment contamination: Review of evidence and need for knowledge. Chemosphere 115:20-30. – reference: Schwab BW, Hayes EP, Fiori JM, Mastrocco FJ, Roden NM, Cragin D, Meyerhoff RD, D'Aco VJ, Anderson PD. 2005. Human pharmaceuticals in US surface waters: A human health risk assessment. Regul Toxicol Pharmacol 42:296-312. – reference: Sarp S, Chon K, Kim IS, Cho J. 2011. Advanced treatment of membrane bioreactor (MBR) effluents for effective wastewater reclamation. Water Sci Technol 63:303-310. – reference: Martz M. 2012. Effective wastewater treatment in the pharmaceutical industry. Pharm Eng 32:1-12. – reference: Cook SM, VanDuinen BJ, Love NG, Skerlos SJ. 2012. Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals. Environ Sci Technol 46:5535-5541. – reference: Gardner M, Comber S, Scrimshaw MD, Cartmell E, Lester J, Ellor B. 2012. The significance of hazardous chemicals in wastewater treatment works effluents. Sci Total Environ 437:363-372. – reference: US Environmental Protection Agency. 1995. Final Water Quality Guidance for the Great Lakes System. Final Rule. 40 CFR Part 9. Fed Reg 60:15365-15425. – reference: US Environmental Protection Agency. 2009. Drinking Water Contaminant Candidate List 3-Final. Fed Reg 74:51850-51862. – reference: Boxall AB, Rudd MA, Brooks BW, Caldwell DJ, Choi K, Hickmann S, Innes E, Ostapyk K, Staveley JP, Verslycke T, Ankley GT, Beazley KF, Belanger SE, Berninger JP, Carriquiriborde P, Coors A, Deleo PC, Dyer SD, Ericson JF, Gagne F, Giesy JP, Gouin T, Hallstrom L, Karlsson MV, Larsson DG, Lazorchak JM, Mastrocco F, McLaughlin A, McMaster ME, Meyerhoff RD, Moore R, Parrott JL, Snape JR, Murray-Smith R, Servos MR, Sibley PK, Straub JO, Szabo ND, Topp E, Tetreault GR, Trudeau VL, Van Der Kraak G. 2012. Pharmaceuticals and personal care products in the environment: What are the big questions? Environ Health Perspect 120:1221-1229. – reference: Kostich MS, Batt AL, Lazorchak JM. 2014. Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation. Environ Pollut 184C:354-359. – year: 2011 – volume: 8 start-page: 649 year: 2011 end-page: 666 article-title: Treatment options for wastewater effluents from pharmaceutical companies publication-title: Int J Environ Sci Tech – volume: 77 start-page: 26072 year: 2012 end-page: 26101 article-title: Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for public water systems. Final Rule. 40 CFR Parts 141 and 142 publication-title: Fed Reg – volume: 9 start-page: 142 year: 2013 end-page: 154 article-title: Landfill disposal of unused medicines reduces surface water releases publication-title: Integr Environ Assess Manag – volume: 202 start-page: 53 year: 2010 end-page: 154 article-title: Occurrence and fate of human pharmaceuticals in the environment publication-title: Rev Environ Contam Toxicol – volume: 44 start-page: 4910 year: 2010 end-page: 4916 article-title: Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents publication-title: Environ Sci Technol – volume: L334 start-page: 17 year: 2010 end-page: 119 article-title: Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emissions (integrated pollution prevention and control) publication-title: Official J Eur Union – year: 2007 – volume: 76 start-page: 122 year: 2006 end-page: 159 article-title: Ecotoxicology of human pharmaceuticals publication-title: Aquat Toxicol – volume: 8 start-page: 320 year: 2012 end-page: 330 article-title: Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach publication-title: Integr Environ Assess Manag – start-page: 284 year: 2009 end-page: 303(220) – volume: 73 start-page: 1612 year: 2010 end-page: 1619 article-title: Characterization of additional sewage treatment technologies: Ecotoxicological effects and levels of selected pharmaceuticals, hormones and endocrine disruptors publication-title: Ecotoxicol Environ Saf – volume: 184C start-page: 354 year: 2014 end-page: 359 article-title: Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation publication-title: Environ Pollut – year: 2016 – volume: 148 start-page: 751 year: 2007 end-page: 755 article-title: Effluent from drug manufactures contains extremely high levels of pharmaceuticals publication-title: J Hazard Mater – year: 1992 – volume: 115 start-page: 20 year: 2014 end-page: 30 article-title: Factory‐discharged pharmaceuticals could be a relevant source of aquatic environment contamination: Review of evidence and need for knowledge publication-title: Chemosphere – year: 2014 – year: 2010 – year: 1998 – year: 2012 – volume: 18 start-page: 77 year: 2006 end-page: 82 article-title: Time out: Longer solids retention times can remove some PPCPs publication-title: Water Environment and Technology – volume: 36 start-page: 15 year: 2010 end-page: 26 article-title: Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes publication-title: Environ Int – volume: 73 start-page: 9628 year: 2008 end-page: 9654 article-title: Drinking Water Contaminant Candidate List 3—Draft publication-title: Fed Reg – volume: 120 start-page: 1221 year: 2012 end-page: 1229 article-title: Pharmaceuticals and personal care products in the environment: What are the big questions publication-title: Environ Health Perspect – volume: 32 start-page: 1 year: 2012 end-page: 12 article-title: Effective wastewater treatment in the pharmaceutical industry publication-title: Pharm Eng – volume: 80 start-page: 6076 year: 2015 end-page: 6084 article-title: Drinking Water Contaminant Candidate List 4—Draft publication-title: Fed Reg – year: 2008 – year: 2006 – volume: 437 start-page: 363 year: 2012 end-page: 372 article-title: The significance of hazardous chemicals in wastewater treatment works effluents publication-title: Sci Total Environ – volume: 42 start-page: 296 year: 2005 end-page: 312 article-title: Human pharmaceuticals in US surface waters: A human health risk assessment publication-title: Regul Toxicol Pharmacol – volume: 37 start-page: 1342 year: 2011 end-page: 1348 article-title: Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges publication-title: Environ Int – volume: 74 start-page: 51850 year: 2009 end-page: 51862 article-title: Drinking Water Contaminant Candidate List 3—Final publication-title: Fed Reg – year: 1995 – volume: 63 start-page: 303 year: 2011 end-page: 310 article-title: Advanced treatment of membrane bioreactor (MBR) effluents for effective wastewater reclamation publication-title: Water Sci Technol – volume: 369 start-page: 20130571 year: 2014 article-title: Pollution from drug manufacturing: Review and perspectives publication-title: Philos Trans R Soc Lond B Biol Sci – volume: 60 start-page: 15365 year: 1995 end-page: 15425 article-title: Final Water Quality Guidance for the Great Lakes System. Final Rule. 40 CFR Part 9 publication-title: Fed Reg – volume: 10 start-page: 576 year: 2014 end-page: 587 article-title: International scientists' priorities for research on pharmaceutical and personal care products in the environment publication-title: Integr Environ Assess Manag – volume: 46 start-page: 5535 year: 2012 end-page: 5541 article-title: Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals publication-title: Environ Sci Technol – year: 2015 – year: 2013 – year: 2010 ident: 2025010315265570700_etc3163-bib-0042 – year: 1992 ident: 2025010315265570700_etc3163-bib-0048 – year: 2006 ident: 2025010315265570700_etc3163-bib-0034 – year: 2015 ident: 2025010315265570700_etc3163-bib-0036 – year: 2007 ident: 2025010315265570700_etc3163-bib-0040 – year: 2014 ident: 2025010315265570700_etc3163-bib-0024 – year: 2014 ident: 2025010315265570700_etc3163-bib-0032 – year: 2013 ident: 2025010315265570700_etc3163-bib-0013 – volume: 73 start-page: 1612 year: 2010 ident: 2025010315265570700_etc3163-bib-0051 article-title: Characterization of additional sewage treatment technologies: Ecotoxicological effects and levels of selected pharmaceuticals, hormones and endocrine disruptors publication-title: Ecotoxicol Environ Saf doi: 10.1016/j.ecoenv.2010.05.012 – start-page: 284 year: 2009 ident: 2025010315265570700_etc3163-bib-0052 – year: 2011 ident: 2025010315265570700_etc3163-bib-0021 – year: 2012 ident: 2025010315265570700_etc3163-bib-0014 – year: 2014 ident: 2025010315265570700_etc3163-bib-0033 – year: 2014 ident: 2025010315265570700_etc3163-bib-0039 – volume: 202 start-page: 53 year: 2010 ident: 2025010315265570700_etc3163-bib-0001 article-title: Occurrence and fate of human pharmaceuticals in the environment publication-title: Rev Environ Contam Toxicol – volume: 437 start-page: 363 year: 2012 ident: 2025010315265570700_etc3163-bib-0022 article-title: The significance of hazardous chemicals in wastewater treatment works effluents publication-title: Sci Total Environ doi: 10.1016/j.scitotenv.2012.07.086 – volume: 77 start-page: 26072 year: 2012 ident: 2025010315265570700_etc3163-bib-0018 article-title: Revisions to the Unregulated Contaminant Monitoring Regulation (UCMR 3) for public water systems. Final Rule. 40 CFR Parts 141 and 142 publication-title: Fed Reg – volume: 63 start-page: 303 year: 2011 ident: 2025010315265570700_etc3163-bib-0054 article-title: Advanced treatment of membrane bioreactor (MBR) effluents for effective wastewater reclamation publication-title: Water Sci Technol doi: 10.2166/wst.2011.054 – volume: 10 start-page: 576 year: 2014 ident: 2025010315265570700_etc3163-bib-0057 article-title: International scientists' priorities for research on pharmaceutical and personal care products in the environment publication-title: Integr Environ Assess Manag doi: 10.1002/ieam.1551 – volume: 42 start-page: 296 year: 2005 ident: 2025010315265570700_etc3163-bib-0030 article-title: Human pharmaceuticals in US surface waters: A human health risk assessment publication-title: Regul Toxicol Pharmacol doi: 10.1016/j.yrtph.2005.05.005 – year: 2014 ident: 2025010315265570700_etc3163-bib-0037 – volume: 8 start-page: 320 year: 2012 ident: 2025010315265570700_etc3163-bib-0029 article-title: Managing emissions of active pharmaceutical ingredients from manufacturing facilities: An environmental quality standard approach publication-title: Integr Environ Assess Manag doi: 10.1002/ieam.1268 – year: 2006 ident: 2025010315265570700_etc3163-bib-0038 – year: 2013 ident: 2025010315265570700_etc3163-bib-0045 – volume: 18 start-page: 77 year: 2006 ident: 2025010315265570700_etc3163-bib-0053 article-title: Time out: Longer solids retention times can remove some PPCPs publication-title: Water Environment and Technology – year: 2014 ident: 2025010315265570700_etc3163-bib-0035 – year: 2006 ident: 2025010315265570700_etc3163-bib-0047 – volume: 115 start-page: 20 year: 2014 ident: 2025010315265570700_etc3163-bib-0005 article-title: Factory-discharged pharmaceuticals could be a relevant source of aquatic environment contamination: Review of evidence and need for knowledge publication-title: Chemosphere doi: 10.1016/j.chemosphere.2014.02.004 – volume: 76 start-page: 122 year: 2006 ident: 2025010315265570700_etc3163-bib-0010 article-title: Ecotoxicology of human pharmaceuticals publication-title: Aquat Toxicol doi: 10.1016/j.aquatox.2005.09.009 – volume: 8 start-page: 649 year: 2011 ident: 2025010315265570700_etc3163-bib-0043 article-title: Treatment options for wastewater effluents from pharmaceutical companies publication-title: Int J Environ Sci Tech doi: 10.1007/BF03326250 – year: 1998 ident: 2025010315265570700_etc3163-bib-0046 – year: 2011 ident: 2025010315265570700_etc3163-bib-0026 – year: 2010 ident: 2025010315265570700_etc3163-bib-0041 – volume: 46 start-page: 5535 year: 2012 ident: 2025010315265570700_etc3163-bib-0004 article-title: Life cycle comparison of environmental emissions from three disposal options for unused pharmaceuticals publication-title: Environ Sci Technol doi: 10.1021/es203987b – volume: 9 start-page: 142 year: 2013 ident: 2025010315265570700_etc3163-bib-0002 article-title: Landfill disposal of unused medicines reduces surface water releases publication-title: Integr Environ Assess Manag doi: 10.1002/ieam.1311 – year: 2012 ident: 2025010315265570700_etc3163-bib-0020 – year: 2015 ident: 2025010315265570700_etc3163-bib-0011 – volume: L334 start-page: 17 year: 2010 ident: 2025010315265570700_etc3163-bib-0023 article-title: Directive 2010/75/EU of the European Parliament and of the Council of 24 November 2010 on industrial emissions (integrated pollution prevention and control) publication-title: Official J Eur Union – volume: 120 start-page: 1221 year: 2012 ident: 2025010315265570700_etc3163-bib-0056 article-title: Pharmaceuticals and personal care products in the environment: What are the big questions publication-title: Environ Health Perspect doi: 10.1289/ehp.1104477 – volume: 36 start-page: 15 year: 2010 ident: 2025010315265570700_etc3163-bib-0049 article-title: Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes publication-title: Environ Int doi: 10.1016/j.envint.2009.09.002 – volume: 80 start-page: 6076 year: 2015 ident: 2025010315265570700_etc3163-bib-0019 article-title: Drinking Water Contaminant Candidate List 4—Draft publication-title: Fed Reg – year: 2016 ident: 2025010315265570700_etc3163-bib-0003 – volume: 148 start-page: 751 year: 2007 ident: 2025010315265570700_etc3163-bib-0009 article-title: Effluent from drug manufactures contains extremely high levels of pharmaceuticals publication-title: J Hazard Mater doi: 10.1016/j.jhazmat.2007.07.008 – volume: 60 start-page: 15365 year: 1995 ident: 2025010315265570700_etc3163-bib-0025 article-title: Final Water Quality Guidance for the Great Lakes System. Final Rule. 40 CFR Part 9 publication-title: Fed Reg – volume: 32 start-page: 1 year: 2012 ident: 2025010315265570700_etc3163-bib-0044 article-title: Effective wastewater treatment in the pharmaceutical industry publication-title: Pharm Eng – year: 2011 ident: 2025010315265570700_etc3163-bib-0027 – year: 2006 ident: 2025010315265570700_etc3163-bib-0028 – volume: 74 start-page: 51850 year: 2009 ident: 2025010315265570700_etc3163-bib-0017 article-title: Drinking Water Contaminant Candidate List 3—Final publication-title: Fed Reg – volume: 44 start-page: 4910 year: 2010 ident: 2025010315265570700_etc3163-bib-0007 article-title: Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents publication-title: Environ Sci Technol doi: 10.1021/es100356f – volume: 184C start-page: 354 year: 2014 ident: 2025010315265570700_etc3163-bib-0050 article-title: Concentrations of prioritized pharmaceuticals in effluents from 50 large wastewater treatment plants in the US and implications for risk estimation publication-title: Environ Pollut doi: 10.1016/j.envpol.2013.09.013 – volume: 37 start-page: 1342 year: 2011 ident: 2025010315265570700_etc3163-bib-0006 article-title: Adverse effects in wild fish living downstream from pharmaceutical manufacture discharges publication-title: Environ Int doi: 10.1016/j.envint.2011.06.002 – volume: 73 start-page: 9628 year: 2008 ident: 2025010315265570700_etc3163-bib-0016 article-title: Drinking Water Contaminant Candidate List 3—Draft publication-title: Fed Reg – year: 2015 ident: 2025010315265570700_etc3163-bib-0015 – year: 1995 ident: 2025010315265570700_etc3163-bib-0031 – year: 2008 ident: 2025010315265570700_etc3163-bib-0012 – volume: 369 start-page: 20130571 year: 2014 ident: 2025010315265570700_etc3163-bib-0008 article-title: Pollution from drug manufacturing: Review and perspectives publication-title: Philos Trans R Soc Lond B Biol Sci doi: 10.1098/rstb.2013.0571 – year: 2015 ident: 2025010315265570700_etc3163-bib-0055 |
SSID | ssj0016999 |
Score | 2.32211 |
SecondaryResourceType | review_article |
Snippet | The present study describes guidance intended to assist pharmaceutical manufacturers in assessing, mitigating, and managing the potential environmental impacts... |
SourceID | proquest pubmed crossref wiley istex fao |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 813 |
SubjectTerms | Active pharmaceutical ingredient case studies compliance Drug Industry Drug-Related Side Effects and Adverse Reactions Effluents Environmental impact Environmental Pollutants - analysis Environmental Pollutants - toxicity Environmental risk ingredients manufacturing Manufacturing industry Maturity path Pharmaceutical Preparations - analysis Pharmaceuticals risk Risk Assessment Risk reduction toxicity Toxicology Waste Water - analysis wastewater Wastewater effluent |
Title | risk‐based approach to managing active pharmaceutical ingredients in manufacturing effluent |
URI | https://api.istex.fr/ark:/67375/WNG-3M90V135-Z/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fetc.3163 https://www.ncbi.nlm.nih.gov/pubmed/26183919 https://www.proquest.com/docview/1774806934 https://www.proquest.com/docview/1775631028 https://www.proquest.com/docview/1803158349 https://www.proquest.com/docview/1808370265 |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9VAEF5sQfDF1mtPrWUFqU9pk91ks_tYpLUILaIeLfqw7FWhek45Jwdsn_oT_I3-Emc2F63UIj4lkFmYzGVnNpn5hpCnJtbcS4S-VLnJSsNVJo3FXhnvXCXqYFJv1eGROBiXL4-r466qEnthWnyI4YMbekbar9HBjZ3v_AINhbeCA6dAoE8s1cJ86PWAHFUIlUZHogFnNROyx53N2U6_8FIkWopmCvkpivbbVcnm5dw1BZ_9FfKxZ7utOTnZXjR2253_gej4f--1Sm53OSndbY3oDrkRJnfJzb2EZ312j-hdigXoPy6-Y8jztIchp82Ufu3GHFGT9k16-vn3T-QUnswC1pQ1c7hH6gV2UqTWSBpimo_S3Cfj_b23zw-ybi5D5iCY88w7pqxT0VvQqBe5VVwIaWUdSiVKY8Cxo-OcC-cLz2zhVYzKV8b5CFtaLPgDsjyZTsIaobWSApiKKnJX1qaWQGMU8yaYADuHHJFnvY6060DLcXbGF93CLTMN4tIorhF5MlCetkAdV9CsgZq1-QRS0-M3DNH14IgI8aAaka2k-2GtmZ1gzVtd6fdHLzQ_VPm7glf6w4hs9MahO3ef6wKSaJkLxUtgY3gMjop_X8wkTBeJphIc87lraCQO3ZC8VNfSIGARE8Dzw9Y4B6bhOAwJbwGrt5KJ_VUSGtSK1_V_JXxEbqG42pqlDbLczBbhMaRjjd0kS6x8tZnc7yfOAjFz |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61RQguvKELBYKEyiltEieOLU4ValmguwfoQoWQLMcPKrXsVtusBJz4CfxGfgkzzgOKSoU47UoZS5N5eMbOzDcAj7UvmRUEfSkTHeeayVjoinplrDEFL50OvVWjMR9O8pf7xf4SPO16YRp8iP7CjTwj7Nfk4HQhvfkLNRRfC0-cnC3DBRroHc5Tr3vsqJTLMDySTDguMy465Nkk2-xWnopFy17PMEMl4X4-K908nb2G8LNzFT50jDdVJ4cbi7raMF__wHT8zze7BlfatDTaauzoOiy56Q24uB0grb_cBLUVUQ36j2_fKerZqEMij-pZ9KmddBTpsHVGxwe_35JH-GTuqKysPsH_RL2gZorQHRk5H0ak1LdgsrO992wYt6MZYoPxnMXWZLIy0tsKlWp5UknGuahE6XLJc63Rt71hjHFjU5tVqZXeS1toYz3uaj5lt2FlOpu6VYhKKTgy5aVnJi91KZBGy8xqpx1uHmIATzolKdPiltP4jCPVIC5nCsWlSFwDeNRTHjdYHWfQrKKelf6IUlOTNxkB7OEpEUNCMYD1oPx-rZ4fUtlbWah34-eKjWTyNmWFej-Atc46VOvxJyrFPFokXLIc2egfo6_SBxg9dbNFoCk4o5TuHBpBczcEy-W5NIRZlHHk-U5jnT3TeCLGnDfF1evBxv4qCYVqpd-7_0r4EC4N90a7avfF-NU9uEyia0qY1mClni_cfczO6upB8MKfj2c0tw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9VAEN4IRsOL4g2Ogq6JwadC2223u48EOOKFE6MeJfiw2e4FEuCck0NPoj75E_yN_hJmthfFIDE-tUlnk-lcdmbbmW8IeaZ9waxA6EsZ6yjTTEZCl9grY43JeeF06K3aG_DdYfZqP99vqiqxF6bGh-g-uKFnhP0aHXxi_cYv0FB4KzhwcjZHrmc8FmjR2-866KiEyzA7Ei04KlIuWuDZON1oV14IRXNejyFBRdl-uSzbvJi8hujTv00-t3zXRSfH67OqXDff_oB0_L8XWyS3mqSUbtZWdIdcc6O75MZOALT-eo-oTYoV6D-__8CYZ2mLQ06rMT1t5hxRHTZOOjn6_Rs5hSdTh0Vl1RncI_UMWylCbyR1PgxIqe6TYX_nw9Zu1AxmiAxEcxZZk8rSSG9LUKnlcSkZ56IUhcskz7QGz_aGMcaNTWxaJlZ6L22ujfWwp_mEPSDzo_HILRNaSMGBKS89M1mhCwE0WqZWO-1g6xA98rzVkTINajkOzzhRNd5yqkBcCsXVI087ykmN1HEJzTKoWelDkJoavk8RXg_OiBAQ8h5ZC7rv1urpMRa9Fbn6NHih2J6MPyYsVwc9stIah2r8_UwlkEWLmEuWARvdY_BU_P2iR248CzQ5Z5jQXUEjcOqGYJm8kgYRi1IOPC_VxtkxDedhyHgTWL0WTOyvklCgVrw-_FfCJ-Tm2-2-evNy8PoRWUDJ1fVLK2S-ms7cKqRmVfk4-OA56-Azbw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+risk-based+approach+to+managing+active+pharmaceutical+ingredients+in+manufacturing+effluent&rft.jtitle=Environmental+toxicology+and+chemistry&rft.au=Caldwell%2C+Daniel+J&rft.au=Mertens%2C+Birgit&rft.au=Kappler%2C+Kelly&rft.au=Senac%2C+Thomas&rft.date=2016-04-01&rft.issn=1552-8618&rft.eissn=1552-8618&rft.volume=35&rft.issue=4&rft.spage=813&rft_id=info:doi/10.1002%2Fetc.3163&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0730-7268&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0730-7268&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0730-7268&client=summon |